Novogen Ltd (NASDAQ:NVGN)
| 4.04 Data as of May 17 |  -0.0499 / -1.22%Today’s Change | 0.48 Today|||52-Week Range 10.49 | +76.65% Year-to-Date |
Latest NVGN News | Press Releases
| 5 Stocks Poised to Break Out May 10 / TheStreet.com |
Today’s Trading
| Previous close | 4.09 |
| Today’s open | 4.07 |
| Day’s range | 4.00 - 4.14 |
| Volume | 19,481 |
| Average volume (3 months) | 222,363 |
| Market cap | $17.0M |
| Dividend yield | -- |
Data as of 3:59pm ET, 05/17/2013
Growth & Valuation
| Earnings growth (last year) | -- |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | +4.00% |
| Revenue growth (last year) | -- |
| P/E ratio | -- |
| Price/Sales | -- |
| Price/Book | 4.77 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| MSLIMerus Labs Internati... | -0.01 | -1.75% |
| TZYMTranzyme Inc | +0.01 | +1.92% |
| DARADARA BioSciences Inc | -0.04 | -5.06% |
| TNXPDTonix Pharmaceutical... | 0.00 | 0.00% |
Data as of 3:59pm ET, 05/17/2013
Financials
| Next reporting date | -- |
| EPS forecast (this quarter) | -- |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | $1.4M |
| Net profit margin | -- |
Profile
Sector Health Technology |
Industry Biotechnology |
Chief Executive Officer & Director Graham E. Kelly, PhD |
Chief Financial Officer Mark G. Hinze, CPA |
Corporate headquarters Sydney, New South Wales (nsw) |
Forecasts
